NL-OMON53661
Not yet recruiting
Not Applicable
Biomarker based intervention strategies to combat adverse effects of shift work - GRIP
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- slaap, vermoeidheid, wellbevinden
- Sponsor
- Erasmus MC, Universitair Medisch Centrum Rotterdam
- Enrollment
- 75
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age 18 to 60 years.
- •Work at least 4 night shifts a month on average.
- •Shift workers, working rotating shifts (morning, evening and night shifts) or
- •working predominantly night shifts. Night shift defined as work at least 1
- •hours between 0:00\- and 6:00\.
- •Work at least 2 night shifts in a row
- •Work \>\= 20 work hours per week.
- •Having a shift duration of 6 h\-12 h.
- •History of \>\= 1 year of working rotating shift work or night shifts prior to
Exclusion Criteria
- •Taking medication that the investigator believes would interfere with the
- •objectives of the study. For example, sleep medication, medication that
- •interferes with glucose homeostasis, and/or anti\-inflammatory drugs.
- •Pregnant or have a wish to become pregnant during the study period.
- •Planned surgery during the entire study period
- •Alcohol consumption \> 21 units/week
- •Severe psychiatric disease and/or any mental or physical disability that will
- •hinder participation in the interventions
- •Severe cardiovascular disease, to the discretion of the study doctor
- •Having a chronic inflammatory disease, including asthma, rheumatic fever,
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 4
Biomarker-guided treatment-and-stop-strategy for recombinant IL-1receptor antagonist (anakinra) in patients with systemic Juvenile Idiopathic Arthritis.Still's diseasesystemic JIA1000381610023213NL-OMON43845niversitair Medisch Centrum Utrecht55
Active, not recruiting
Phase 1
Biomarker-guided treatment-and-stop-strategy for short acting IL-1 blockade in patients with systemic Juvenile Idiopathic Arthritis.systemic Juvenile Idiopathic ArthritisTherapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2015-004393-16-NLniversity Medical Center Utrecht
Active, not recruiting
Phase 2
Genetic, immune and treatment-related differences in cancers of the mouth and throat in India.Health Condition 1: C32- Malignant neoplasm of larynxHealth Condition 2: C00-C14- Malignant neoplasms of lip, oral cavity and pharynxCTRI/2020/10/028482ational Institutes of Health USA
Recruiting
Not Applicable
Biomarker discovery and development of therapy for aortic aneurysmAortic aneurysmJPRN-UMIN000010927Yokohama City University Graduate School of Medicine150
Recruiting
Not Applicable
Identification of biomarkers in patients with diabetic macular edemaJPRN-jRCT1080223989SANTEN PHARMACEUTICAL CO., LTD.36